Staphylococcus aureus Infections - Development of A Novel, Effective Vaccine

More than 30% of people carry *Staphylococcus aureus* in their noses and on their skin, and when surgery or an implanted device lets the bacterium into the body, it can cause pneumonia or life-threatening blood infections—especially the antibiotic-resistant MRSA form. Every attempt to create a vaccine against *S. aureus* has failed in human trials, despite promising results in animals. This project, led by Absynth Biologics Limited and the University of Sheffield, aims to break that pattern. The team is combining novel vaccine targets with technologies designed to provoke a stronger, more targeted response from the human immune system. They are also drawing on a deeper understanding of how the infection actually develops in the body—both physiologically and immunologically—to choose the most promising candidate for clinical testing. If the research succeeds, it would produce the first effective vaccine against a bacterium that causes thousands of serious hospital infections each year. That would reduce the need for last-resort antibiotics, lower the risk of sepsis in surgical patients, and cut the burden on intensive care units. For people with hip replacements, heart valves, or other implants, a working vaccine could mean the difference between a routine recovery and a life-threatening complication.